Hubble Therapeutics Advances in Gene Therapy with $7.3M Series A
Deal News | Mar 25, 2025 | PR Newswire Cision Hubble Therapeutics LLC
Hubble Therapeutics LLC, a biotechnology company focused on innovations in gene therapy for pediatric blindness, announced the successful close of a $7.3 million Series A financing round. The funds will support the advancement of their lead candidate, HUB-101, aimed at treating Leber Congenital Amaurosis Type 16 (LCA16) and Snowflake Vitreoretinal Degeneration (SVD). These are severe retinal dystrophies resulting from mutations in the KCNJ13 gene. Initiatives include moving HUB-101 into human clinical trials expected by 2026. Development partners include Andelyn Biosciences and Virscio, and the scientific foundation is based on research from Dr. Bikash Pattnaik at the University of Wisconsin-Madison. The investment, led by the Wisconsin Alumni Research Foundation (WARF), exemplifies the power of academic-industry partnerships in driving transformative medical research.
Sectors
- Biotechnology
- Healthcare
- Pharmaceuticals
Geography
- United States – Hubble Therapeutics is based in Hanover, New Hampshire, working with strategic partners in Columbus, Ohio, and New Haven, Connecticut.
Industry
- Biotechnology – The article focuses on Hubble Therapeutics' gene therapy development, which falls under the biotechnology industry that involves therapeutic innovations.
- Healthcare – Hubble Therapeutics' work on treatments for retinal disorders like LCA16 and SVD places the company within the healthcare sector, specifically targeting pediatric blindness.
- Pharmaceuticals – The development and anticipated clinical trials of HUB-101 align with pharmaceutical activities focusing on new drug development.
Financials
- $7.3 million – The amount raised in the Series A funding round to advance HUB-101 into clinical trials.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Hubble Therapeutics LLC | Target company | Company | A biotechnology firm developing gene therapy for pediatric blindness. |
| Bikash Pattnaik | Co-founder and Scientific Lead | Person | Professor at University of Wisconsin-Madison, pivotal in research behind the HUB-101 therapy. |
| Wisconsin Alumni Research Foundation (WARF) | Co-lead investor | Company | Research foundation supporting academic-industry partnerships, invested in Hubble Therapeutics. |
| University of Wisconsin-Madison | Research Institution | Company | The institution where the foundational research for HUB-101 was conducted. |
| Andelyn Biosciences | Development Partner | Company | Partnering with Hubble Therapeutics for development and manufacturing of HUB-101. |
| Virscio | Research Partner | Company | Partnering with Hubble Therapeutics for conducting IND-enabling studies. |